NCT06962176Recruiting
Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The goal of this clinical study is to find out which treatment works best for people with persistent atrial fibrillation (a type of irregular heartbeat). Researchers are comparing two types of heart ablation procedures: * An anterior mitral line ablation (a treatment at the front part of the heart) * A posterior mitral line ablation (at the back of the heart), sometimes with an extra step using a small vein called the Vein of Marshall The main questions the study aims to answer are: * Which approach works better at fixing the heart rhythm? * Which approach is safer (less complications)? People who take part in this study will: * Undergo an ablation procedure as part of their standard care * Attend follow-up visits at 1, 3, and 6 months * Have tests like ECGs, heart ultrasound (echocardiogram), blood tests, heart rhythm monitors (Holter), and a heart CT scan
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- First submitted
- 22 Apr 2025
- Start date
- 24 Sept 2026
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- AZ Sint-Jan AV
- Diseases
- Atrial fibrillation
- NCT number
- NCT06962176
What you commit to
- Study type: Interventional
- Planned participants: 146
- From 24 Sept 2026 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous mitral line or any other left atrial ablation beyond pulmonary vein isolation
- Cardiac surgery within the previous 90 days.
- Percutaneous transluminal coronary angioplasty/stenting or myocardial infarction within the previous 30 days.
- Documented history of a thromboembolic event within the previous 60 days.
Other illness
- Expecting cardiac transplantation or other cardiac surgery within 180 days.
- Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.
- Acute illness or active infection at time of index procedure
- Renal insufficiency
- Unstable angina.
- History of blood clotting or bleeding abnormalities.
- Uncontrolled heart failure.
- Presence of a condition that precludes vascular access.
Lab values
- Left ventricular ejection fraction \<25%.
- International normalised ratio (INR) greater than 4 within 24 hours of procedure - for patients taking warfarin.
Other
- Left atrial (LA) thrombus. LA thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.
- LA diameter greater than 60 mm on long axis parasternal view, or left atrial volume more than 250 cc.
- Diagnosed atrial myxoma.
- Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
- Women who are pregnant or who plan to become pregnant during the study.
- Contraindication to anticoagulation.
- Life expectancy less than 1 year.
- Unwilling or unable to provide informed consent.
Who the study is looking for
- Patients between the ages of 18 and 80 years, diagnosed with symptomatic persistent AF with clinical indication for left atrial ablation with a mitral isthmus line. Pulmonary vein will be isolated in all patients before starting the mitral isthmus line (during a previous or the same procedure)
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Az Sint-Jan Brugge Av Coordinator of this site? Confirm its status | Bruges | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.